Sign in Register

Indication

Bone marrow suppression due to folic acid antagonism

Bone marrow suppression due to folic acid antagonism is an iatrogenic hematologic toxicity characterized by impaired production of blood cell lineages within the hematopoietic system. Read more about Bone marrow suppression due to folic acid antagonism

45 drugs 36 manufacturers

Advertisement

Drugs that treat it

Common Bone marrow suppression due to folic acid antagonism therapies.

Showing 1–9 of 45 drugs

LEUCOVORIN CALCIUM

FOLIC ACID·FOLIC ACID DEFICIENT MEGALOBLASTIC ANEMIA·+7
SAGENT PHARMACE
Filter & compare in the drug finder →Opens the drug finder with Bone marrow suppression due to folic acid antagonism preselected.

News & literature

Coming soon

Related codes

Coming soon

Related conditions & guidelines

Coming soon

About Bone marrow suppression due to folic acid antagonism.

Bone marrow suppression due to folic acid antagonism is an iatrogenic hematologic toxicity characterized by impaired production of blood cell lineages within the hematopoietic system.

It occurs when folate antagonists, such as methotrexate, trimethoprim, or pyrimethamine, inhibit dihydrofolate reductase or downstream folate-dependent pathways, depleting intracellular tetrahydrofolate pools.

This disruption halts purine and thymidylate synthesis, impeding DNA replication and cell division in rapidly proliferating hematopoietic precursor cells.

Clinically, this suppression manifests across affected patient populations as single or multilineage cytopenias, including neutropenia, thrombocytopenia, and megaloblastic anemia.

Personalize your experience

Follow Bone marrow suppression due to folic acid antagonism and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it